Drug
Fostamatinib clinical trials
Also written Tavalisse.
- studies test it
- 53
- open now
- 5
- in phase 3
- 12
- first study started
- 2006
Keep track of what changes. Save the fostamatinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Development codes
Studies by the year they started
53 studies that test it; most in 2011 (8)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2007 | 2 |
| 2008 | 4 |
| 2009 | 2 |
| 2010 | 6 |
| 2011 | 8 |
| 2012 | 6 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 2 |
| 2018 | 1 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 20
- Phase 2
- 26
- Phase 3
- 12
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 37 · Other 16
AstraZeneca (21) · Rigel Pharmaceuticals (15) · National Heart, Lung, and Blood Institute (NHLBI) (5) · Imperial College London (2) · Stefanie Sarantopoulos, MD, PhD. (2) · Kissei Pharmaceutical Co., Ltd. (1) · M.D. Anderson Cancer Center (1) · Sean Collins (1)
Often tested with
Tested in the same studies.
Ruxolitinib (2) · Talfirastide (1) · Sar-Arg-Val-Tyr-Ile-His-Pro-Ala-OH (1) · Rosuvastatin (1) · Simvastatin (1) · Pioglitazone (1)
Studies
Open first, then newest update. How each study uses fostamatinib is read from its arms, and is right about nine times in ten.
Testing it · 53
- Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific AntibodiesRecruitingPhase 1National Heart, Lung, and Blood Institute (NHLBI)NCT06948097Written as fostamatinib
- Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell DiseaseRecruitingPhase 1National Heart, Lung, and Blood Institute (NHLBI)NCT05904093Written as Fostamatinib
- Fostamatinib for Treating Acute Respiratory Distress Syndrome (ARDS) in Hospitalized AdultsNot yet recruitingPhase 2Inova Health Care ServicesNCT06564207Written as Fostamatinib
- Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHDRecruitingPhase 1Stefanie Sarantopoulos, MD, PhD.NCT06233110Written as Fostamatinib
- A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic AnemiaEnrolling by invitationPhase 3Rigel PharmaceuticalsNCT04138927Written as Fostamatinib disodium
- Using Fostamatinib to Treat Post-Hematopoietic Stem Cell Transplant Immune-mediated CytopeniasTerminatedPhase 2National Heart, Lung, and Blood Institute (NHLBI)NCT05502783Written as fostamatinib
- Inflammatory Signal Inhibitors for COVID-19 (MATIS)CompletedPhase 1/2Imperial College LondonNCT04581954Written as Fostamatinib
- Extension Study (Extended Access) of Syk-inhibition Using Fostamatinib to Treat Posttransplant Immune-mediated CytopeniasWithdrawnPhase 2National Heart, Lung, and Blood Institute (NHLBI)NCT05509582Written as fostamatinib
- A Clinical Study in Patients With Chronic Idiopathic Thrombocytopenic Purpura in R788CompletedPhase 3Kissei Pharmaceutical Co., Ltd.NCT04132050Written as R788
- International Sites: Novel Experimental COVID-19 Therapies Affecting Host ResponseTerminatedPhase 2/3NEAT ID FoundationNCT05593770Written as Fostamatinib
- Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy with Hypomethylating AgentsCompletedPhase 1M.D. Anderson Cancer CenterNCT05030675Written as Fostamatinib
- Novel Experimental COVID-19 Therapies Affecting Host ResponseCompletedPhase 2/3Sean CollinsNCT04924660Written as Fostamatinib
- Fostamatinib in the Treatment of Chronic Active Antibody Mediated RejectionActive, not recruitingPhase 1/2Imperial College LondonNCT03991780Written as Fostamatinib
- Clinical Trial of Combined Fostamatinib and Paclitaxel in Ovarian CancerCompletedPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT03246074Written as Fostamatinib 100 mg bid and Paclitaxel
- Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)CompletedPhase 3Rigel PharmaceuticalsNCT02077192Written as Fostamatinib Disodium
- A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHACompletedPhase 3Rigel PharmaceuticalsNCT03764618Written as Fostamatinib disodium
- Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell TransplantCompletedPhase 1Stefanie Sarantopoulos, MD, PhD.NCT02611063Written as fostamatinib
- Study of the Effect of Fostamatinib Upon Cutaneous Inflammation in the Setting of Hidradenitis SuppurativaCompletedPhase 2Holdsworth House Medical PracticeNCT05040698Written as Fostamatinib
- Fostamatinib for Hospitalized Adults With COVID-19CompletedPhase 2National Heart, Lung, and Blood Institute (NHLBI)NCT04579393Written as fostamatinib
- A Safety and Efficacy Study of R935788 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia (AIHA)CompletedPhase 2Rigel PharmaceuticalsNCT02612558Written as Fostamatinib 150 mg bid
See all 53 studies that test fostamatinib →
Given in every arm · 2 — fostamatinib is usual care beside what is tested
- Fostamatinib as a Single Agent or in Combination With Ruxolitinib for Treatment of Patients With Myelofibrosis With Severe ThrombocytopeniaTerminatedPhase 2Washington University School of MedicineNCT04543279Written as Fostamatinib
- Effects of Administration of Fostamatinib on Blood Concentrations of Rifampicin in Healthy Subjects.CompletedPhase 1AstraZenecaNCT01336218Written as fostamatinib
As the comparator · 1 — what is tested is compared with fostamatinib
Codes
What other systems call fostamatinib · ClinicalTrials.gg INT005170
- MeSH (NLM) C523665fostamatinibOne source NLM
- UNII (FDA) SQ8A3S5101FOSTAMATINIBConfirmed FDA, NLM, Wikidata
- RxNorm 2044896One source FDA
- Wikidata Q5473550fostamatinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C95222FostamatinibOne source FDA
- DrugBank DB12010One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C523665 | fostamatinib | One source NLM |
| UNII (FDA) | SQ8A3S5101 | FOSTAMATINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2044896 | — | One source FDA |
| Wikidata | Q5473550 | fostamatinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C95222 | Fostamatinib | One source FDA |
| DrugBank | DB12010 | — | One source Wikidata |
Also registered as fostamatinib disodium (UNII 86EEZ49YVB · RxNorm 2055929) and fostamatinib disodium anhydrous (UNII X9417132K8).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.